THE MANUFACTURERS of a coronavirus vaccine used around the world yesterday confirmed a third dose of their jab "neutralises" the Omicron variant.
"Results from an initial laboratory study demonstrating that serum antibodies induced by the Pfizer-BioNTech Covid-19 vaccine neutralise the SARSCoV-2 Omicron variant after three doses," the companies announced in a trading update yesterday.
The update comes as Prime Minister
Work from home advice has been reinstated and people will have to wear masks in a wider range of settings under the new rules.
Proof of Covid-19 status will also be required to enter larger venues such as football stadiums and nightclubs.
Initial findings show "a third dose could still offer a sufficient level of protection from disease of any severity caused by the Omicron variant," said
Sahin echoed Bourla's call for countries across the world to step up their booster vaccination programmes "to better protect people everywhere and to get through the winter season," he said.
Although the findings were upbeat, the results of the study are preliminary.
However, they are the first indication from a key vaccine maker that suggest existing jabs could hold back the Omicron variant.
(c) 2021 City A.M., source